Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
Bristol Myers Squibb (NYSE:BMY) primarily generates its revenue by developing and selling prescription therapeutic medications for oncology and cardiovascular health worldwide.
It recently secured expanded regulatory approvals from the U.S. Food and Drug Administration for its targeted cardiovascular treatments, and it separately entered a strategic partnership with Nvidia to deploy advanced artificial intelligence computing systems specifically designed to accelerate its ongoing early drug discovery efforts.
Eli Lilly (NYSE:LLY) earns most of its revenue by discovering and commercializing specialized human medicines for diabetes and oncology.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.